Merck KGaA bets on cancer drugs to revitalise German firm

TEL AVIV, Oct 12 (Reuters) - Merck KGaA is betting on its oncology pipeline to revitalise the German drugmaker as it sees falling sales from its best-selling medicine, multiple sclerosis treatment Rebif.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.